CUE VS CYT Stock Comparison

Performance

CUE
10/100

CUE returned -33.33% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

CYT
100/100

CYT returned 95.51% in the last 12 months. Based on SPY's performance of -13.79%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

CUE
75/100

1 analysts offer 12-month price targets for CUE. Together, they have an average target of 7, the most optimistic target put CUE at 7 within 12-months and the most pessimistic has CUE at 7.

CYT

"Analyst Price Targets" not found for CYT

Sentiment

CUE
74/100

CUE had a bullish sentiment score of 74.32% across Twitter and StockTwits over the last 12 months. It had an average of 2.59 posts, 1.65 comments, and 3.88 likes per day.

CYT

"Sentiment" not found for CYT

Technicals

CUE
64/100

CUE receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

CYT
93/100

CYT receives a 92 of 100 based on 14 indicators. 12 are bullish, 0 are bearish.

Earnings

CUE
10/100

CUE has missed earnings 6 times in the last 20 quarters.

CYT
54/100

CYT has missed earnings 2 times in the last 20 quarters.

Profit

CUE
10/100

Out of the last 20 quarters, CUE has had 0 profitable quarters and has increased their profits year over year on 0 of them.

CYT
10/100

Out of the last 15 quarters, CYT has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

CUE
40/100

CUE has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.

CYT
57/100

CYT has had a higher than average amount of volatility over the last 12 months giving it a score of 57 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Cue Biopharma, Inc. Summary

Nasdaq / CUE

Healthcare

Biotechnology

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Cyteir Therapeutics, Inc. Common Stock Summary

Nasdaq / CYT

Healthcare

Biotechnology

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.

Power up your portfolio